Low-Risk Prostate Cancer Surveillance: USMLE Review of New Data

A new analysis of US data, published in CANCER, finds that low-risk prostate cancer is being diagnosed less often than it was in 2010. Patients who do receive that diagnosis are far more likely to avoid radiation and prostate removal. The authors link this to earlier concerns about overdiagnosis and overtreatment, which had hindered PSA-based screening. This is a trend analysis: it shows how practice has changed, not whether patients' outcomes are better.

What happened

Researchers looked at localized prostate cancer in three data sources:

• SEER (Surveillance, Epidemiology, and End Results Program), 2010–2023
• The Veterans Affairs (VA) health system, 2010–2024
• The Michigan Radiation Oncology Quality Consortium (MROQC), 2021–2025

The background is familiar. During the 2010s, recommendations supporting prostate-specific antigen (PSA)–based screening wavered. The worry was unnecessary treatment of slow-growing, localized cancers that posed no threat to patients' lives. Guidelines in turn supported active surveillance for low-risk disease. The new study asks whether that guidance actually changed what happens to patients.

The reported numbers:

• Share of low-risk disease at diagnosis: it fell from 28.8% to 24.0% in SEER and from 32.3% to 21.9% in the VA.
• Patients with low-risk cancer who received neither radiation nor prostatectomy: this rose from 33.6% to 83.4% (2023) in SEER and from 51.6% to 96.3% (2024) in the VA.
• Low-risk disease among patients treated with radiation: among 207,196 patients treated with radiation for localized prostate cancer, the low-risk share fell from 33.7% to 6.5% in SEER and from 22.9% to 2.0% in the VA. In the more recent MROQC cohort it stayed low, between 2.8% and 4.2% from 2021 to 2025.

Lead author Steven M. Monda, M.D., MSCI, of the University of Michigan said the moderate decline in low-risk diagnoses likely reflects more MRI use in screening. He added that most low-risk cancer is now being appropriately observed rather than treated.

Why it matters

Prostate cancer is a classic example of the tension in screening medicine. PSA can detect cancers early, but it also finds many tumors that would never have caused symptoms or shortened life. Treating those tumors exposes men to the harms of surgery or radiation with little expected benefit. Those harms include erectile dysfunction, urinary incontinence and bowel irritation.

According to this analysis, the system is separating "cancer that needs treatment" from "cancer that needs watching" more effectively than it did in 2010. For students, the study is a real-world case of how evidence about screening harms changes clinical behavior.

What to know for the USMLE — prostate cancer, PSA and active surveillance

• Epidemiology and pathology: Most prostate cancers are acinar adenocarcinomas and arise in the peripheral zone. That is why many are palpable on digital rectal exam, while BPH arises in the transition zone and causes urinary obstruction.
• PSA: a serine protease (kallikrein) made by prostatic epithelium that liquefies semen. It is organ-specific, not cancer-specific. It rises in BPH, prostatitis, urinary retention, instrumentation and ejaculation. 5-alpha-reductase inhibitors (finasteride, dutasteride) lower PSA by roughly half, which matters when interpreting values.
• Grading: The Gleason score and ISUP Grade Group reflect glandular architecture. Grade Group 1 (Gleason 6) is the lowest-grade cancer. Low-risk disease is generally defined by low clinical stage, Grade Group 1 and a PSA below 10 ng/mL. These are textbook criteria, not details taken from this study.
• Active surveillance: a plan of scheduled PSA testing, periodic exam, repeat biopsy and often MRI, with treatment only if there is progression. It differs from watchful waiting, which is symptom-driven and non-curative, used in patients with limited life expectancy.
• Screening biases (high-yield):
• Overdiagnosis: detecting a cancer that would never have caused harm in the patient's lifetime.
• Lead-time bias: earlier detection makes survival look longer without changing the time of death.
• Length-time bias: screening preferentially finds slow-growing, indolent tumors.

Prostate cancer screening is a standard vignette for all three.

• Screening guidance: The USPSTF moved from recommending against PSA screening (Grade D, 2012) to individualized decision-making for men aged 55–69 (Grade C, 2018). Expect questions on shared decision-making: discuss the potential benefit of reduced mortality against the harms of false positives, biopsy complications and overtreatment.
• Treatment-related harms: Radical prostatectomy can cause erectile dysfunction and stress incontinence through injury to the cavernous nerves and the sphincter. Radiation can cause proctitis, cystitis and urethral stricture, and has a small risk of secondary malignancy.
• Advanced disease: it spreads to bone, with osteoblastic lesions and elevated alkaline phosphatase. It is treated with androgen deprivation therapy (GnRH agonists such as leuprolide, with a possible initial testosterone flare, or antiandrogens such as flutamide and bicalutamide). Spinal metastasis with cord compression is an emergency.

Limitations

• This is a trends analysis, not an outcome study. It describes changes in diagnosis and treatment patterns. It does not show that fewer treatments led to better or worse survival, quality of life or fewer harms. The "big win" language in the quote is the investigators' interpretation.
• The MRI explanation is a likely cause, not a proven one. The authors say the decline in low-risk diagnoses likely reflects more MRI in screening. The source material does not say this was directly tested.
• "Neither radiation nor prostatectomy" is not identical to "active surveillance." The reported measure is the absence of those two treatments. We would need more detail, which the source does not provide, to say how many of these men were in a formal surveillance program.
• The data sources differ. SEER is a population-based cancer registry. The VA is an integrated health system with its own patient population. MROQC is a regional quality consortium and covers a shorter, more recent period. The time windows also differ (2023, 2024, 2025), so direct comparisons should be made cautiously.
• The radiation analysis only covers treated patients. A falling share of low-risk disease among those treated with radiation shows that radiation is going to higher-risk patients. It cannot tell us about patients who were not treated.
• Registry data have limits. This is observational data. The source gives no information on confounders or on how risk was classified in each dataset beyond "low risk."

FAQ

What is low-risk prostate cancer?

It is localized prostate cancer with features suggesting a slow-growing tumor. For exam purposes, think low clinical stage, Grade Group 1 (Gleason 6) and a low PSA. The study used its own risk classification, and the source material does not detail it.

Does this study show that active surveillance is safe?

No. It shows that fewer low-risk cancers are being treated with radiation or prostatectomy. It does not measure survival or cancer progression. The safety evidence for surveillance comes from other studies and is not part of this news item.

Why does PSA screening cause overdiagnosis?

PSA detects biologically indolent cancers along with aggressive ones. Many of the indolent tumors would never have caused symptoms or death. Finding and treating them adds harm without benefit. This is why screening decisions are individualized.

Key takeaways

• In US data from 2010 onward, low-risk prostate cancer made up a smaller share of new diagnoses (28.8% to 24.0% in SEER; 32.3% to 21.9% in the VA).
• Among men with low-risk disease, receipt of neither radiation nor prostatectomy rose sharply (to 83.4% in SEER and 96.3% in the VA by the latest years).
• This is observational trend data. It shows that practice shifted toward less overtreatment, but it does not prove better outcomes. For the USMLE, know the PSA limitations, the screening biases and the logic of active surveillance for low-risk disease.